Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | KCNA2 | P16389 | 1/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.47 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.47 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590791 | 0.92 | ALDH1A1 (0.52) | ALDH1A1USP2TSHRHSD17B10LTB4R | |
| SCHEMBL2299912 | 0.90 | PTGER4 (0.47) | ALDH1A1TSHRHSD17B10KDM4ELMNA | |
| SCHEMBL2300382 | 0.89 | PTGER4 (0.46) | ALDH1A1TSHRHSD17B10KDM4ELMNA | |
| SCHEMBL2300372 | 0.89 | PTGER4 (0.46) | ALDH1A1TSHRHSD17B10KDM4ELMNA | |
| SCHEMBL1590385 | 0.88 | ALDH1A1 (0.47) | ALDH1A1USP2TSHRHSD17B10LTB4R | |
| SCHEMBL1591366 | 0.88 | KCNA3 (0.55) | ALDH1A1USP2TSHRHSD17B10KDM4E | |
| SCHEMBL1590733 | 0.87 | KMT2A (0.50) | ALDH1A1USP2TSHRHSD17B10KDM4E | |
| SCHEMBL14431116 | 0.84 | ALDH1A1 (0.44) | ALDH1A1USP2TSHRHSD17B10LTB4R | |
| SCHEMBL4609391 | 0.84 | ALDH1A1 (0.49) | ALDH1A1USP2TSHRHSD17B10LTB4R | |
| SCHEMBL1590125 | 0.84 | EDNRA (0.52) | ALDH1A1USP2TSHRHSD17B10LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979317-B1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LTD (GB) | 2012-08-22 | — | — | EP | disclosed |
| US-8207213-B2 | Benzoisoindole derivatives for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8207213-B2 | Benzoisoindole derivatives for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8207213-B2 | Benzoisoindole derivatives for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-8026270-B2 | Benzo [F] isoindoles as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2011-09-27 | — | — | US | disclosed |
| US-8026270-B2 | Benzo [F] isoindoles as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2011-09-27 | — | — | US | disclosed |
| US-8026270-B2 | Benzo [F] isoindoles as EP4 receptor agonists | GLAXO GROUP LIMITED (GB) | 2011-09-27 | — | — | US | disclosed |
| US-20110092561-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2011-04-21 | — | — | US | disclosed |
| US-20110092561-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2011-04-21 | — | — | US | disclosed |
| US-20110092561-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2011-04-21 | — | — | US | disclosed |
| EP-2049485-A1 | NAPHTHALENE DERIVATIVES USED AS EP4 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009019281-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009019281-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2009-02-12 | — | — | WO | disclosed |
| EP-1979317-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008061955-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008061955-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008012344-A1 | NAPHTHALENE DERIVATIVES USED AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012344-A1 | NAPHTHALENE DERIVATIVES USED AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008012347-A1 | BENZO [F] ISOINDOLES AS EP4 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007088189-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092561-A1 | BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN | OPRK1, OPRD1, OPRL1 | ALDH1A1 1159/4885USP2 4495/4885TSHR 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.